141 related articles for article (PubMed ID: 32945180)
1. Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience.
Kumar N; Gy S; Dracham CB; Dey T; Madan R; Khosla D; Oinum A; Kapoor R
CNS Oncol; 2020 Sep; 9(3):CNS60. PubMed ID: 32945180
[No Abstract] [Full Text] [Related]
2. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric advantage of intensity-modulated radiotherapy for whole ventricles in the treatment of localized intracranial germinoma.
Sakanaka K; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e273-80. PubMed ID: 21640515
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
5. IMRT or 3D-CRT in glioblastoma? A dosimetric criterion for patient selection.
Lorentini S; Amelio D; Giri MG; Fellin F; Meliado G; Rizzotti A; Amichetti M; Schwarz M
Technol Cancer Res Treat; 2013 Oct; 12(5):411-20. PubMed ID: 23617288
[TBL] [Abstract][Full Text] [Related]
6. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
7. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric study of different radiotherapy planning approaches for hippocampal avoidance whole-brain radiation therapy (HA-WBRT) based on fused CT and MRI imaging.
Wang BH; Hua W; Gu X; Wang XL; Li J; Liu LQ; Huang YX
Australas Phys Eng Sci Med; 2015 Dec; 38(4):767-75. PubMed ID: 26577714
[TBL] [Abstract][Full Text] [Related]
9. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
[TBL] [Abstract][Full Text] [Related]
10. Potential for reduced radiation-induced toxicity using intensity-modulated arc therapy for whole-brain radiotherapy with hippocampal sparing.
Pokhrel D; Sood S; Lominska C; Kumar P; Badkul R; Jiang H; Wang F
J Appl Clin Med Phys; 2015 Sep; 16(5):131–141. PubMed ID: 26699321
[TBL] [Abstract][Full Text] [Related]
11. Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: a feasibility study.
Nicolini G; Ghosh-Laskar S; Shrivastava SK; Banerjee S; Chaudhary S; Agarwal JP; Munshi A; Clivio A; Fogliata A; Mancosu P; Vanetti E; Cozzi L
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):553-60. PubMed ID: 22386376
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma : A dosimetric comparison.
Adeberg S; Harrabi SB; Bougatf N; Bernhardt D; Rieber J; Koerber SA; Syed M; Sprave T; Mohr A; Abdollahi A; Haberer T; Combs SE; Herfarth K; Debus J; Rieken S
Strahlenther Onkol; 2016 Nov; 192(11):770-779. PubMed ID: 27334276
[TBL] [Abstract][Full Text] [Related]
13. Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy.
Thibouw D; Truc G; Bertaut A; Chevalier C; Aubignac L; Mirjolet C
J Neurooncol; 2018 Apr; 137(2):429-438. PubMed ID: 29374810
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain?
Hermanto U; Frija EK; Lii MJ; Chang EL; Mahajan A; Woo SY
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1135-44. PubMed ID: 17208388
[TBL] [Abstract][Full Text] [Related]
15. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study.
Szczepanek D; Marchel A; Moskała M; Krupa M; Kunert P; Trojanowski T
Neurol Neurochir Pol; 2013; 47(2):101-8. PubMed ID: 23649997
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk.
Buglione M; Spiazzi L; Saiani F; Costa L; Shehi B; Lazzari B; Uccelli C; Pasinetti N; Borghetti P; Triggiani L; Donadoni L; Pedretti S; Magrini SM;
Tumori; 2014; 100(3):272-7. PubMed ID: 25076237
[TBL] [Abstract][Full Text] [Related]
20. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
